Alzheimer's disease

Scandal aside, Biogen's Aduhelm sales set to reach $1B next year and $6B+ by 2025: analysts
Fierce Pharma
Tue, 07/20/21 - 12:37 pm
Biogen
Aduhelm
Alzheimer's disease
Major health centers, insurers push back against Aduhelm
BioPharma Dive
Thu, 07/15/21 - 11:16 pm
Biogen
Aduhelm
insurers
Alzheimer's disease
Lilly and Banner Alzheimer’s Institute in strategic research collaboration for donanemab trial
Biopharma Reporter
Thu, 07/15/21 - 12:27 pm
Eli Lilly
Banner Alzheimer's Institute
donanemab
clinical trials
Alzheimer's disease
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg
Thu, 07/15/21 - 10:45 am
Biogen
Eisai
Alzheimer's disease
lecanemab
BAN2401
FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
Stat
Wed, 07/14/21 - 10:37 pm
Janet Woodcock
FDA
Biogen
Aduhelm
Alzheimer's disease
Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff — report
Endpoints
Wed, 07/14/21 - 10:50 am
Biogen
Aduhelm
insurers
Alzheimer's disease
FDA staffers defend Aduhelm approval in JAMA editorial
Pharmaforum
Wed, 07/14/21 - 10:18 am
FDA
Biogen
Aduhelm
JAMA
drug approvals
Alzheimer's disease
So far, so not-so-good: Neurologists slow to warm up to Biogen’s Alzheimer drug Aduhelm, study finds
Fierce Pharma
Tue, 07/13/21 - 11:43 pm
Biogen
Aduhelm
neurologists
Alzheimer's disease
How’s my driving? GPS tracking spots Alzheimer’s with 86% accuracy
Pharmaforum
Tue, 07/13/21 - 10:57 am
diagnostics
GPS tracking
biomarkers
Alzheimer's disease
House committees kick off investigation into how Biogen's Aduhelm won approval
Endpoints
Tue, 07/13/21 - 10:48 am
US Congress
Biogen
Aduhelm
FDA
drug approvals
Alzheimer's disease
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
BioPharma Dive
Mon, 07/12/21 - 11:39 pm
CMS
Medicare
Biogen
Aduhelm
Alzheimer's disease
FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment
BioPharma Dive
Thu, 07/8/21 - 11:17 am
Biogen
Aduhelm
FDA
Alzheimer's disease
labeling
Eli Lilly makes modest bet on 'all-in-human' discovery outfit for ALS drugs, deepening bid in precision neurology
Endpoints
Thu, 07/8/21 - 11:02 am
Eli Lilly
Verge Genomics
drug development
drug discovery
artificial intelligence
ALS
Alzheimer's disease
Lundbeck sells off flopped Alzheimer's drug as Aduhelm approval ups interest
Fierce Biotech
Fri, 07/2/21 - 11:05 am
Lundbeck
Denovo Biopharma
Alzheimer's disease
GSK, under pressure to perform, pens $2.2B deal with Alector focused on neuro R&D, Alzheimer's
Fierce Biotech
Fri, 07/2/21 - 11:00 am
GSK
biobucks
Alector
neurodegenerative disease
Alzheimer's disease
All in on amyloid, Acumen Pharma’s IPO raises $160M for Alzheimer’s drug R&D
MedCity News
Fri, 07/2/21 - 10:54 am
Acumen Pharmaceuticals
IPOs
Alzheimer's disease
Roche to seek early FDA approval for Alzheimer’s therapy: Jefferies
Seeking Alpha
Thu, 07/1/21 - 10:45 am
Roche
FDA
Alzheimer's disease
gantenerumab
ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits
Endpoints
Wed, 06/30/21 - 11:04 am
Biogen
ICER
Aduhelm
Alzheimer's disease
drug pricing
FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report
Endpoints
Tue, 06/29/21 - 11:05 am
FDA
Biogen
Aduhelm
accelerated approvals
Alzheimer's disease
Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
Stat
Mon, 06/28/21 - 10:44 am
Biogen
Aduhelm
FDA
Medicare
Alzheimer's disease

Pages